Shares of Halozyme spike 17% after positive results for pancreatic cancer drug
January 05, 2017 at 19:09 PM EST
Jim Cramer spoke with Halozyme Therapeutics' CEO on its results for phase 2 pancreatic cancer drug.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.